The case continues on ERISA and pre-2020 contract claims, meaning ongoing legal costs and potential settlement pressure. Monitor for summary judgment or trial developments; a large damages award is not yet in sight.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 9 $78.84entry
- T+1 · 7mo ago +0.62%α +0.69% · $79.33
- T+5 · 7mo ago −2.60%α −5.80% · $76.79
- T+20 · 6mo ago +10.81%α +3.21% · $87.36
- T+60 · 4mo ago +32.33%α +22.36% · $104.33
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
In ER Addison LLC v. Aetna Health Inc., the court partially granted Aetna's motion to dismiss, dismissing negligent misrepresentation, unjust enrichment, state-law breach of contract for post-2020 services (lack of standing), and ERISA-preempted contract claims. However, the core ERISA claim and state-law contract claims for pre-2020 services survive. This is a modest procedural win for Aetna/CVS, but material litigation risk remains given the thousands of alleged underpayment claims.
Court Ruling Details
Key Facts
- Court dismissed negligent misrepresentation and unjust enrichment claims under Rule 12(b)(6).
- State-law breach of contract claims for post-January 2020 services dismissed for lack of Article III standing (insureds faced no financial harm due to Texas balance-billing prohibition).
- ERISA preempts state-law breach of contract claims based on ERISA-regulated plans.
- ERISA claim and state-law breach of contract claims for pre-2020 services survive the motion.
- Plaintiff alleges 3,452–3,620 claims of underpayment; no specific dollar amount stated in the ruling.
Financial Impact
No damages awarded or quantified in this ruling; potential exposure from thousands of underpayment claims remains unknown.
Risk Factors
- Adverse trial outcome on remaining claims could require Aetna to pay higher reimbursement rates.
- Potential for class certification or aggregated claims to increase exposure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3jmnoy9t-CVS |
Track record
25 reports on CVS
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +32.33% at T+60 after the Apr 8, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago Court Ruling Neutral 3/10 Entry price pending
- Nov 6, 20269d ago Insider Buy Bullish 4/10 Entry $85.25 Now $88.47 +3.78% settles Dec 8
- Nov 4, 202612d ago 8-K Neutral 6/10 Entry $79.96 Now $88.47 +10.64% settles Dec 3
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $79.96 Now $88.47 +10.64% settles Dec 3
- Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $92.53 Now $88.47 −4.39% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 2/10 Entry $92.58 to $89.79 Now $88.47 −4.44% ▼ −3.01% −1.11% vs SPY
- Sep 30, 20266w ago Press Release Neutral 2/10 Entry $85.20 to $90.33 Now $88.47 +3.84% ▲ +6.02% +5.32% vs SPY
- Aug 5, 202614w ago 8-K Bullish 8/10 Entry $99.12 to $97.23 Now $88.47 −10.74% ▼ −1.91% −1.31% vs SPY
- Jul 10, 202618w ago Press Release Neutral 2/10 Entry $104.15 to $95.46 Now $88.47 −15.06% ▼ −8.35% −10.77% vs SPY
- Jun 29, 202620w ago Court Ruling Bullish 5/10 Entry $103.58 to $107.74 Now $88.47 −14.59% ▲ +4.02% +4.30% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers